Hansa Medical Ab

Genovis Ab

Mattias Collin

Maria Allhorn

Jonathan Sjögren

Falk Nimmerjahn

Lars Björck

Rikard Holmdahl

Lars Bjorck

Rolf Lood

Kutty Selva Nandakumar

Arne Olsén

Oonagh Shannon

Anders Olin

Karl Carlstrom

Jonathan Sjogren

Arne Olsen

Karl CARLSTRÖM

The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.

Treatment for IgE-mediated disease

The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated fromstrain NZ131 and is a homolog of EndoS. EndoS49 has specific endoglycosidase activity on native IgG and cleaves a larger variety of Fc glycans than EndoS. A mutant thereof where the glutamic acid at position 186 of SEQ ID NO: 1 was substituted was produced: said mutant lacks endoglycosidase activity but is capable of binding to IgG. Methods using EndoS49, deletions thereof and said mutant, especially for assessing glycosylation of IgG or for isolating IgG are disclosed.

[object Object]

The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.

Use of the endoglycosidase endos for treating immunoglobulin G mediated diseases

The inventions provides methods and kits for the dissociation of Fc&#x3b3;-receptor-IgG complexes, and methods and kits for the isolation of IgG and Fc and Fab fragments of IgG.

Method of assessing glycosylation state or functional quality of an IgG containing sample

Growing community of inventors

Lund, Sweden

Mattias Collin